1-20 of 213
Thomas J. Kipps, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Jan A. Burger, MD PhD, Tadeusz Robak, MDPhD, Fatih Demirkan, MD, Osnat Bairey, MD, Carol Moreno, MD PhD, David Simpson, MBChB, FRACP, FRCPA, Talha Munir, MBBS, Don A. Stevens, MD, Sandra Dai, PhD MS, Leo W. K. Cheung, PhD, Kevin Kwei, PhD, Indu Lal, MD, Emily Hsu, PhD, Thomas J. Kipps, MD PhD, Alessandra Tedeschi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-134437
Published: 2020
Journal Articles

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Hun Ju Lee, MD, Michael Y. Choi, MD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Jacqueline C. Barrientos, MD, Nicole Lamanna, MD, Alec Goldenberg, MD, Iris Isufi, MD, Joseph Tuscano, MD, Suki Subbiah, MD, Jean L. Koff, MD, Lori A. Leslie, MD, Gina G Chung, MD, Elizabeth K Weihe, MD, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Frank J Hsu, MD, Michael Wang, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-141917
Published: 2020
Journal Articles

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

Benjamin Heyman, MD, Michael Y. Choi, MD, Emanuela M. Ghia, PhD, George F. Widhopf II, PhD, Minya Pu, PhD, Emily Pittman, PhD, Karen Messer, PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13.
https://doi.org/10.1182/blood-2020-134711
Published: 2020
Journal Articles

Genetic Determinants and Evolutionary History of Richter's Syndrome

Erin Michelle Parry, MD PhD, Romain Guieze, MD, Ignaty Leshchiner, PhD, Daniel Rosebrock, Bria Persaud, Camilla K Lemvigh, MSc, Eugen Tausch, MD, Matthew S. Davids, MD, Johannes Bloehdorn, MD, Christof Schneider, MD, Liudmila Elagina, Aina Zurita Martinez, Amaro Taylor-Weiner, PhD, Nitin Jain, MD, William G. Wierda, MD PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD PhD, Julien Broséus, Florence Cymbalista, MD PhD, Neil E. Kay, MD, Kenneth J. Livak, PhD, Shuqiang Li, PhD, Teddy Huang, BS, Noelia Purroy, MD PhD, Annabelle J Anandappa, MD, Stacey M. Fernandes, BS, Filippo Utro, PhD, Kahn Rhrissorrakrai, PhD, Chaya Levovitz, MD PhD, Brian P Danysh, PhD, Kara Slowik, Sameer A. Parikh, MD, Jennifer R Brown, MD PhD, Laxmi Parida, PhD, Donna S. Neuberg, ScD, Stephan Stilgenbauer, MD, Gad Getz, PhD, Catherine J. Wu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–48.
https://doi.org/10.1182/blood-2020-139456
Published: 2020
Journal Articles

IKZF3 Overexpression Phenocopies Gain-of-Function Mutation in Chronic Lymphocytic Leukemia

Shanye Yin, PhD, Gregory Lazarian, PharmD, Elisa Ten Hacken, PhD, Tomasz Sewastianik, PhD, Satyen Gohil, BSc, MBBS, MRCP, FRCPath, Shuqiang Li, PhD, Laura Z. Rassenti, PhD, Leah Billington, BA, Elizabeth Witten, Teddy Huang, BS, Kenneth J. Livak, PhD, Donna S. Neuberg, ScD, Fanny Baran-Marszak, MD PhD, Thomas J. Kipps, MD PhD, Florence Cymbalista, MD PhD, Ruben D. Carrasco, MD PhD, Catherine J. Wu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9.
https://doi.org/10.1182/blood-2020-137085
Published: 2020
Journal Articles

The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL

Binyamin A. Knisbacher, PhD, Ziao Lin, BS, Cynthia K. Hahn, MD PhD, Ferran Nadeu, Martí Duran-Ferrer, Kristen E. Stevenson, MS, Eugen Tausch, MD, Alex Barbera-Mourelle, Andrew Dunford, Shankara Anand, Julio Delgado, MD, Julian M. Hess, Amaro Taylor-Weiner, PhD, Helene Kretzmer, PhD, Pablo Bousquets Muñoz, Conner J. Shaughnessy, Stacey M. Fernandes, BS, Mariela Sivina, Laura Z. Rassenti, PhD, Alexander Meissner, PhD, Adrian Wiestner, MD PhD, Jan A. Burger, MD PhD, Thomas J. Kipps, MD PhD, Jennifer R Brown, MD PhD, Michael Hallek, François Aguet, PhD, Donna S. Neuberg, ScD, Xose S Puente, PhD, Chip Stewart, PhD, José I. Martín-Subero, PhD, Stephan Stilgenbauer, MD, Catherine J. Wu, MD, Elías Campo, MD PhD, Gad Getz, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-140987
Published: 2020
Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

William G. Wierda, MD PhD, Constantine S. Tam, MD, John N. Allan, MD, Tanya Siddiqi, MD, Thomas J. Kipps, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, Alessandra Tedeschi, MD, Xavier C. Badoux, MBBS, FRACP, FRCPA, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Sharon Jackson, MD, Carol Moreno, MD PhD, Ryan Jacobs, MD, John M. Pagel, MD PhD, Ian W. Flinn, MD PhD, Cathy Zhou, MS, Edith Szafer-Glusman, PhD, Joi Ninomoto, PharmD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Paolo Ghia, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-134446
Published: 2020
Journal Articles

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Arnon P. Kater, MDPhD, Thomas J. Kipps, MD PhD, Barbara Eichhorst, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath, James D'Rozario, Carolyn Owen, MDFRCPC, Sarit E Assouline, MD MSc, Nicole Lamanna, MD, Tadeusz J. Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, MD PhD, Marco Montillo, Clemens Mellink, Brenda J. Chyla, Cameron Wilson, Jenny Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, John F. Seymour
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–21.
https://doi.org/10.1182/blood-2020-136109
Published: 2020
Journal Articles

Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Lin Yang, PhD, Ken Ogasawara, PhD MPH, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-140491
Published: 2020
Journal Articles

Expression of Sf3b1-K700E accelerates the Development of Chronic Lymphocytic Leukemia in a Del (13q) Murine Model

Bo Zhang, MDPhD, Prajish Iyer, PhD, Meiling Jin, PhD, Elisa Ten Hacken, PhD, Zachary Cartun, BS, Kevyn Hart, BS, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD PhD, Donna S. Neuberg, ScD, Ruben D. Carrasco, MD PhD, Catherine J. Wu, MD, Lili Wang, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-139096
Published: 2020
Journal Articles

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Michael Y. Choi, MD, Emanuela M. Ghia, PhD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Hun Ju Lee, Jacqueline C. Barrientos, MD MS, Nicole Lamanna, MD, Alec Goldenberg, Dimitrios Tzachanis, MD PhD, Erin G. Reid, MD MS, Elizabeth K Weihe, MD, Laura Z. Rassenti, PhD, Iris Isufi, MD, Stewart Bieler, BA, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1755.
https://doi.org/10.1182/blood-2019-131498
Published: 2019
Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Constantine S. Tam, MBBS, MD, Tanya Siddiqi, MD, John N. Allan, MD, Thomas J. Kipps, MD PhD, Ian W. Flinn, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Stephen Opat, Paul M. Barr, MD, Alessandra Tedeschi, MD, Ryan Jacobs, MD, Xavier C. Badoux, MBBS, FRACP, FRCPA, Paolo Ghia, MD PhD, Juthamas Sukbuntherng, PhD, Ahmed Hamed Salem, PhD FCP, Kristin Russell, BS, Karl Eckert, BA, Cathy Zhou, MS, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 35.
https://doi.org/10.1182/blood-2019-121424
Published: 2019
Journal Articles

Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL

Danielle M. Brander, MD, John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Shuo Ma, MD PhD, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Michael Y. Choi, MD, Kathryn Humphrey, BSc, Abdullah Al Masud, PhD, Ruby Nandam, RN, MSN, Amanda Jacobson, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3036.
https://doi.org/10.1182/blood-2019-126508
Published: 2019
Journal Articles

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 503.
https://doi.org/10.1182/blood-2019-127603
Published: 2019
Journal Articles

High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic Leukemia

Emanuela M. Ghia, PhD, Laura Z. Rassenti, PhD, Michael Y. Choi, MD, Elvin Chu, George F. Widhopf II, PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 476.
https://doi.org/10.1182/blood-2019-131426
Published: 2019
Journal Articles

Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, MBBS, PhD FRACP, Thomas J. Kipps, MD PhD, Barbara F. Eichhorst, MD, Peter Hillmen, MD PhD, James D'Rozario, MBBS, FRACP, FRCPA, Sarit Assouline, MD, Carolyn Owen, MD, Tadeusz Robak, MD, Javier de la Serna, MD PhD, Ulrich Jaeger, MD, Guillaume Cartron, Marco Montillo, MD, Nicole Lamanna, MD, Su Young Kim, MD PhD, Jenny Wu, MS, Yanwen Jiang, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Arnon P Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 355.
https://doi.org/10.1182/blood-2019-123930
Published: 2019
Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Arnon P Kater, MD PhD, Jenny Qun Wu, MS, Julie Dubois, Christopher R Bolen, PhD, Zoe J Assaf, PhD, Peter Hillmen, MD PhD, Barbara F. Eichhorst, MD, Eric F Eldering, PhD, Thomas J. Kipps, MD PhD, Anton W Langerak, PhD, Clemens Mellink, PhD, Anne-Marie Van Der Kevie-Kersemaekers, PhD, Carolyn Owen, MD, Brenda J Chyla, PhD, Elizabeth A Punnoose, PhD, Jue Wang, PhD, Marcus Lefebure, PhD BSc, Michelle Boyer, PhD, Kathryn Humphrey, BSc, Yanwen Jiang, PhD, John F. Seymour, MBBS, PhD FRACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 356.
https://doi.org/10.1182/blood-2019-123678
Published: 2019
Journal Articles

Wnt5a Induces ROR1-Dependent Upregulation of MMP9 and Enhanced Invasiveness in Chronic Lymphocytic Leukemia

Md Kamrul Hasan, PhD, Laura Z. Rassenti, PhD, George F. Widhopf II, PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4274.
https://doi.org/10.1182/blood-2019-131600
Published: 2019
Journal Articles

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Shanye Yin, PhD, Salma Parvin, PhD, Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Heather Joyal, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Matthew S. Davids, MD, Ruben D. Carrasco, MD PhD, Anthony G. Letai, MD PhD, Catherine J. Wu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4281.
https://doi.org/10.1182/blood-2019-127293
Published: 2019
Journal Articles

Activation of NF-Kappa B-p62-NRF2 Signaling Supports the Survival of CLL Cells That Express High Levels of ROR1

Elsa Sanchez-Lopez, PhD, Emanuela M. Ghia, PhD, Laura Antonucci, PhD, Laura Z. Rassenti, PhD, Yun Chen, PhD, Thomas J. Kipps, MD PhD, Michael Karin, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3122.
https://doi.org/10.1182/blood-2018-99-115564
Published: 2018